Quest Selling HemoCue to Danaher's Radiometer; Fitch Affirms Quest's BBB+ Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Quest announced today a definitive agreement to sell its HemoCue business to Danaher's Radiometer Medical for about $300 million.

Separately, Fitch Ratings affirmed Quest Diagnostics' Issuer Default Rating at BBB+ after the close of the market on Friday.

Based in Cypress, Calif., HemoCue develops hemoglobin, glucose, and other point-of-care testing systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, the New York Times reports.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.